Optimizing the manufacturing process
Manufacturing CAR T cells is a labor-intensive procedure. At present, the process from leukapheresis to T cell infusion takes approximately two to four weeks. In this interval, the patient’s condition may substantially deteriorate. Therefore, scientists are exploring approaches to reduce the complexity of the manufacturing process. For instance, scientists at UCL are developing more efficient CAR T cell production platforms in collaboration with the company Miltenyi (the Prodigy platform, presented by Claire Roddie). This fully closed system reduces the number of cell manipulation steps, resulting in more standardized CAR T products.
Watch and learn from Professor Roddie’s presentation: